神经元抗体检测与 Lambert-Eaton 肌无力综合征中肺癌预测的改善。
Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.
机构信息
Department of Neurology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham NG7 2UH, UK.
Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
出版信息
J Neuroimmunol. 2020 Mar 15;340:577149. doi: 10.1016/j.jneuroim.2020.577149. Epub 2020 Jan 10.
Since approximately 50% of patients with Lambert-Eaton myasthenic syndrome (LEMS) subsequently develop small-cell lung cancer (SCLC), it is important to be able to predict cancer occurrence in these patients at neurological presentation. We aimed to determine whether circulating biomarkers were effective and objective predictors of cancer development in LEMS. We found that the presence of either SOX2, N-type voltage gated calcium channel or GABAb antibodies at LEMS diagnosis was highly sensitive (84%) and specific (87%) for the detection of SCLC. Screening for SOX2 and neuronal antibodies is a useful adjunct to clinical predictive scoring tools in predicting SCLC in LEMS.
由于大约 50% 的 Lambert-Eaton 肌无力综合征（LEMS）患者随后会发展为小细胞肺癌（SCLC），因此能够在神经学表现时预测这些患者的癌症发生非常重要。我们旨在确定循环生物标志物是否是 LEMS 中癌症发展的有效和客观预测因子。我们发现，在 LEMS 诊断时存在 SOX2、N 型电压门控钙通道或 GABAb 抗体，对 SCLC 的检测具有高度敏感性（84%）和特异性（87%）。在 LEMS 中筛查 SOX2 和神经元抗体是预测 SCLC 的临床预测评分工具的有用辅助手段。
Zotero 插件